Sarah Bos

129 General discussion 7 References 1. Bos S, Blokzijl H, van den Boom B, Lisman T, Adelmeijer J, Kamphuisen P, et al. Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thromb Haemost. 2019;119(02):246–53. 2. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: Causes and consequences. J Thromb Haemost. 2011;9(9):1713–23. 3. Lisman T, Bakhtiari K, Pereboom ITA, Hendriks HGD, Meijers JCM, Porte RJ. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. Journal of Hepatology. 2010. p. 355–61. 4. Vinholt PJ, Alnor AB, Nybo M, Hvas A-M. The primary haemostasis is more preserved in thrombocytopenic patients with liver cirrhosis than cancer. Blood Coagul Fibrinolysis. 2018;(29):307/313. 5. Sinegre T, Duron C, Lecompte T, Pereira B, Massoulier S, Lamblin G, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost. 2018;16:1–9. 6. LebretonA, SinegreT, PereiraB, LamblinG, DuronC, Abergel A. Plasmahypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. J Gastroenterol Hepatol. 2017 Apr;32(4):916–24. 7. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005 Mar;41(3):553–8. 8. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8(9):1994–2000. 9. Groeneveld D, Porte RJ, Lisman T. Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. Thromb Res. 2014;134(3):753–6. 10. Kleiss SF, Adelmeijer J, Meijers JCM, Porte RJ, Lisman T. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. Thromb Res. 2016;140:36–40. 11. Russo FP, Zanetto A, Campello E, Bulato C, Shalaby S, Spiezia L, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct- acting antivirals. Liver Int. 2018;1–9. 12. Kleinegris MC, Habets CAM, Van De Sande AJP, Henskens YMC, Ten Cate-Hoek AJ, Van Deursen C, et al. Liver cirrhosis is associated with hypercoagulability, decreased clot strength and normal fibrinolysis. J Thromb Haemost. 2013;11(May):49–50. 13. Amitrano L, GuardascioneMA, Menchise A, Martino R, ScaglioneM, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44(6):448–51. 14. Intagliata NM, Maitland H, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis. Curr Treat Options Gastroenterol. 2016;14(2):247–56. 15. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, et al. Antithrombotic treatment with direct-acting oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37(5):694–9.